Real-World Evidence Helps Open Accelerated Approval Pathway For Neurodegeneration Therapies

Clene’s ALS drug CNM-Au8 and UniQure’s gene therapy for Huntington’s disease emerged from US FDA discussions with accelerated approval plans using real-world evidence from compassionate use and natural history data sources.